During the corresponding time, Enovis Corp recorded a revenue increase by 5.42 % year on year, sequentially revenue grew by 2.21 %. While revenue at the Enovis Corp's corporate clients
Enovis's Comment on Sales, Marketing and Customers
Enovis serves a range of healthcare professionals, including orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, and athletic trainers. The company's Prevention & Recovery segment provides products for musculoskeletal condition treatment, injury prevention, and at-home physical therapy, utilized by healthcare professionals and retail consumers. The Reconstructive segment offers surgical solutions for joint replacement, limb reconstruction, and foot and ankle procedures, catering to orthopedic surgeons and healthcare systems globally. Enovis distributes its medical devices and related products through independent distributors and direct sales representatives across multiple patient treatment settings.
Enovis, a leading medical technology company, recently introduced the AltiVate Reverse Glenoid System, a breakthrough solution that broadens the range of patients who can benefit from the AltiVate Reverse shoulder prosthesis. The system incorporates a new full-range solution, including a bone-sparing baseplate, peripheral fixation, and glenosphere options, while still maintaining the hallmark simplicity and efficiency of the previous model.This significant development was marked by the successful first surgery using the AltiVate Reverse Glenoid System, performed by Dr. Mark Frankle at Tampa General Hospital on Monday, July 8, 2024. This groundbreaking procedure demonstrates the potential of the new system to...
Enovis Introduces the DonJoy ROAM OA Knee Brace: The Future of Unloader BracesEnovis, a leading healthcare technology company, has recently unveiled an impressive breakthrough in the field of knee braces with the introduction of the DonJoy ROAM OA Knee Brace. This latest innovation in unloader braces promises to revolutionize the way individuals suffering from osteoarthritis (OA) manage their knee pain, offering a comfortable, easy-to-use, and highly effective solution.Osteoarthritis is a degenerative joint disease that commonly affects the knees, causing pain, stiffness, and a significant reduction in mobility. For many individuals living with OA, the constant discomfort and limitations imposed by the condi...
Enovis’s Comment on Sales, Marketing and Customers
Enovis serves a range of healthcare professionals, including orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, and athletic trainers. The company's Prevention & Recovery segment provides products for musculoskeletal condition treatment, injury prevention, and at-home physical therapy, utilized by healthcare professionals and retail consumers. The Reconstructive segment offers surgical solutions for joint replacement, limb reconstruction, and foot and ankle procedures, catering to orthopedic surgeons and healthcare systems globally. Enovis distributes its medical devices and related products through independent distributors and direct sales representatives across multiple patient treatment settings.
Sources:
Enovis Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Enovis Corp’s corporate clients.
For your research, we’ve provided 9 tables on Enovis Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
96.14 %